Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cetirizine Hydrochloride

FDA-approved product (tablet, oral), marketed as Cetirizine Hydrochloride, Cetirizine Hydrochloride Allergy, Cetirizine Hydrochloride Hives and 11 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cetirizine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Allergic rhinitis
  • Eye allergy
  • Nasal congestion
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Piperazine derivatives; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cetirizine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cetirizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS

    NCT07626099 · start 2028-06-30

    Registered record
    Registry ID
    NCT07626099
    Conditions
    Allergic Rhinitis (AR)
    Interventions
    AYURVEDA treatment protocol; Control(Citrizine 10mg)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2028-06-30
    Completion
    2030-12-30
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis (AR)
    InterventionAYURVEDA treatment protocol; Control(Citrizine 10mg)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life

    NCT07478315 · start 2026-03-15

    Registered record
    Registry ID
    NCT07478315
    Conditions
    Breast Cancer
    Interventions
    withdrawal of the premedication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-03-15
    Completion
    2026-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionwithdrawal of the premedication
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg

    NCT04071821 · start 2025-05-01

    Registered record
    Registry ID
    NCT04071821
    Conditions
    Allergy
    Interventions
    cetirizine HCl Gummy; Zyrtec tablet 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2025-05-01
    Completion
    2025-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergy
    Interventioncetirizine HCl Gummy; Zyrtec tablet 10mg
    PhasePhase 1
    Registry statusUnknown

  • The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life

    NCT06535087 · start 2024-07-20

    Registered record
    Registry ID
    NCT06535087
    Conditions
    Pediatric Asthma; Rhinitis, Allergic; Quality of Life
    Interventions
    Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-07-20
    Completion
    2027-05-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Asthma; Rhinitis, Allergic; Quality of Life
    InterventionSubcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment

    NCT06118710 · start 2024-06-25

    Registered record
    Registry ID
    NCT06118710
    Conditions
    Cancer
    Interventions
    Dexamethasone; H1 Antihistaminics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-06-25
    Completion
    2027-08-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionDexamethasone; H1 Antihistaminics
    PhasePhase 4
    Registry statusRecruiting

  • Topical Cetirizine in Treatment of Localized Alopecia Areata

    NCT05803070 · start 2023-09-01

    Registered record
    Registry ID
    NCT05803070
    Conditions
    Alopecia Areata
    Interventions
    Topical Cetirizine 1 %; Topical betamethasone valerate 0.1%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-09-01
    Completion
    2024-10-01
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionTopical Cetirizine 1 %; Topical betamethasone valerate 0.1%
    PhaseNot recorded
    Registry statusUnknown

  • The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

    NCT06039137 · start 2022-06-01

    Registered record
    Registry ID
    NCT06039137
    Conditions
    Solid Tumor
    Interventions
    Cetirizine; Clemastine IV
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-01
    Completion
    2023-10-31
    Enrolment
    395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionCetirizine; Clemastine IV
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients

    NCT05275933 · start 2022-04-05

    Registered record
    Registry ID
    NCT05275933
    Conditions
    COVID-19
    Interventions
    TCM intervention; Placebo intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-04-05
    Completion
    2023-11-22
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionTCM intervention; Placebo intervention
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

    NCT05095311 · start 2021-05-19

    Registered record
    Registry ID
    NCT05095311
    Conditions
    Exercise-induced Arterial Hypoxemia
    Interventions
    Cetirizine HCl; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-05-19
    Completion
    2022-04-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExercise-induced Arterial Hypoxemia
    InterventionCetirizine HCl; Placebo
    PhasePhase 4
    Registry statusTerminated

  • C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

    NCT04935515 · start 2021-04-15

    Registered record
    Registry ID
    NCT04935515
    Conditions
    COVID -19
    Interventions
    Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins; Oral low dose steroid; Intravenous Antibiotics with Low dose steroid.; Oral anti-coagulant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-04-15
    Completion
    2021-06-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID -19
    InterventionOral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins; Oral low dose steroid; Intravenous Antibiotics with Low dose steroid.; Oral anti-coagulant
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

    NCT06754410 · start 2021-03-01

    Registered record
    Registry ID
    NCT06754410
    Conditions
    Lower Ureteric Stones
    Interventions
    Tamsulosin; Cetirizine; Cetirizine + Tamsulosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2024-03-01
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Ureteric Stones
    InterventionTamsulosin; Cetirizine; Cetirizine + Tamsulosin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis

    NCT04706559 · start 2021-01-03

    Registered record
    Registry ID
    NCT04706559
    Conditions
    Atopic Dermatitis
    Interventions
    Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-03
    Completion
    2021-12-15
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionProbiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii; Conventional treatment
    PhaseNot applicable
    Registry statusCompleted

  • Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children

    NCT06288334 · start 2020-08-06

    Registered record
    Registry ID
    NCT06288334
    Conditions
    Allergic Disease; Children
    Interventions
    1-3 Cetirizine Pharmacokinetic samples
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-08-06
    Completion
    2024-05-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Disease; Children
    Intervention1-3 Cetirizine Pharmacokinetic samples
    PhasePhase 4
    Registry statusUnknown

  • Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

    NCT04293822 · start 2020-06

    Registered record
    Registry ID
    NCT04293822
    Conditions
    Androgenetic Alopecia
    Interventions
    Cetirizine; Minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06
    Completion
    2021-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia
    InterventionCetirizine; Minoxidil
    PhasePhase 4
    Registry statusUnknown

  • Cetirizine Chewable Bioequivalence and Food Effect Study

    NCT03772158 · start 2018-12-11

    Registered record
    Registry ID
    NCT03772158
    Conditions
    Allergy
    Interventions
    Cetirizine 10mg; Cetirizine 10 mg; Cetirizine 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-11
    Completion
    2019-02-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergy
    InterventionCetirizine 10mg; Cetirizine 10 mg; Cetirizine 10 mg
    PhasePhase 1
    Registry statusCompleted